Lipella Pharmaceuticals (LIPO) Stock Price, News & Analysis

Company Overview

Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.

Key Stats

• Today's Range: $0.02 to $0.03
• 50-Day Range: $0.02 to $0.18
• 52-Week Range: $0.02 to $3.17
• Volume: 844 shs
• Average Volume: 18,221 shs
• Market Capitalization: $122.92 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

LIPO Stock Analysis - Frequently Asked Questions

How have LIPO shares performed this year?

Lipella Pharmaceuticals' stock was trading at $0.18 at the beginning of 2026. Since then, LIPO stock has decreased by 85.2% and is now trading at $0.0266.

How were Lipella Pharmaceuticals' earnings last quarter?

Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) announced its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.64) EPS for the quarter. The firm earned $0.13 million during the quarter. Lipella Pharmaceuticals had a negative net margin of 988.83% and a negative trailing twelve-month return on equity of 224.08%.

When did Lipella Pharmaceuticals' stock split?

Lipella Pharmaceuticals shares reverse split on Friday, November 8th 2024.A 1-8 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 7th 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

When did Lipella Pharmaceuticals IPO?

Lipella Pharmaceuticals (LIPO) raised $7 million in an IPO on Tuesday, December 20th 2022. The company issued 1,217,391 shares at $5.75-$6.25 per share.

How do I buy shares of Lipella Pharmaceuticals?

Shares of LIPO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Lipella Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lipella Pharmaceuticals investors own include Sangamo Therapeutics (SGMO), MSP Recovery (LIFW), NVIDIA (NVDA), Heatwurx (PCSA), Energy Transfer (ET), Labor Smart (LTNC) and NIO (NIO).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 5/06/2026
• Next Earnings (Estimated): 6/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LIPO
• CIK: 1347242
• Web: lipella.com
• Phone: 412-901-0315
• Fax: N/A
• Employees: 4
• Year Founded: 2005

Profitability

• EPS (Trailing Twelve Months): ($2.42)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$5.02 million
• Net Margins: -988.83%
• Pretax Margin: -988.63%
• Return on Equity: -224.08%
• Return on Assets: -172.88%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.21
• Quick Ratio: 6.21

Sales & Book Value

• Annual Sales: $536.36 thousand
• Price / Sales: 0.23
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.59 per share
• Price / Book: 0.02

Miscellaneous

• Outstanding Shares: 4,621,000
• Free Float: 3,033,000
• Market Cap: $122.92 thousand
• Optionable: Not Optionable
• Beta: 0.83